Cellenkosinc

About Cellenkosinc

Cellenkos Inc., a clinical-stage biotechnology company headquartered in Houston, Texas, operates at the forefront of cellular therapy, focusing on treatments for autoimmune diseases and inflammatory disorders. The company was established in 2016 through a collaboration between Dr. Simrit Parmar of The University of Texas MD Anderson Cancer Center (MDACC) and Golden Meditech Holdings Ltd. The foundation of Cellenkos was the licensing of a proprietary T-regulatory (Treg) cell therapy platform developed in Dr. Parmar's research laboratories at MDACC.

Dr. Parmar's journey as a stem cell transplant physician at MDACC, where she witnessed patients succumb to graft-versus-host disease (GVHD) after successful cancer treatments, fueled her mission to find better solutions. This experience led to the development of a cord blood-derived Treg cell therapy platform, which became the cornerstone of Cellenkos. The company has since advanced this technology, securing a $15 million Series A financing in November 2021, led by BioVeda China Fund, to further its development programs. In April 2022, Global Cord Blood Corporation announced its acquisition of Cellenkos, aiming to expand into the cell therapy market.

Cellenkos's core business revolves around developing allogeneic, 'off-the-shelf' Treg cell therapies. These therapies utilize T-regulatory cells, which act as the immune system's peacekeepers by suppressing excessive immune responses and inflammation. The company's proprietary CRANE® (Cord Blood Regulatory T-cells Activated and eNriched) platform technology is central to its operations. This platform allows for the selection, activation, and enrichment of specific Treg cells from umbilical cord blood, tailoring them to target different diseases. A key advantage of using umbilical cord blood is that the cells are naive and can be administered to patients without requiring HLA matching or lymphodepletion, simplifying treatment. The resulting products are cryopreserved and available on-demand for infusion in an outpatient setting.

The company's robust clinical pipeline targets a range of high-unmet-need conditions. Key products include CK0801 for bone marrow failure syndromes like aplastic anemia , CK0802 for acute respiratory distress syndrome (ARDS) , CK0803 for amyotrophic lateral sclerosis (ALS) , and CK0804 for myelofibrosis. These therapies are designed to home in on inflammatory hotspots in the body, leveraging the cells' natural 'GPS' to deliver targeted therapeutic effects. For instance, CK0804 is enriched with CXCR4 to target the bone marrow in myelofibrosis patients. Cellenkos operates its own in-house cGMP manufacturing facility, which enables large-scale production, with multiple doses derivable from a single umbilical cord unit.